Metformina + Sitagliptina Krka

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformina + Sitagliptina Krka, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise and monotherapy are insufficient. GNH USA supplies Metformina + Sitagliptina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Krka is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder that impairs glucose regulation. It helps achieve glycaemic targets when combined with lifestyle measures. - Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels and reduces HbA1c. - Inadequate control on metformin alone: provides additional glucose‑lowering effect. - Adjunct to diet and exercise: supports overall metabolic management.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or flatulence. - Diarrhoea: loose stools occurring especially after therapy initiation. - Upper respiratory symptoms: nasopharyngitis or mild cough. - Headache: transient cranial pain. - Decreased appetite: reduced food intake. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute pancreatitis: sudden abdominal pain with elevated enzymes. - Hepatic failure: signs of liver dysfunction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Anaphylactic reaction: rare systemic allergic response.

Patients should be evaluated for specific risk factors before initiating therapy and monitored regularly during treatment. - Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic impairment: use with caution; monitor liver enzymes. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or dehydration. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Concomitant medications: review for potential interactions, especially with insulin or sulfonylureas. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina + Sitagliptina Krka may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Iodinated contrast agents: may precipitate acute renal failure, raising lactic acidosis risk. - Cimetidine: can elevate metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Corticosteroids: can raise blood glucose, reducing efficacy. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Rifampicin: may reduce sitagliptin levels. - Anticoagulants (e.g., warfarin): monitor INR as glycaemic changes can affect coagulation.